Study S003245

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT06062069
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 111
Start: 2023-10-19
Primary completion: 2025-07-09
Lead sponsor: Carmot Therapeutics, Inc.
Conditions: Overweight; Obese; Type 1 Diabetes Mellitus
Interventions: DRUG:CT-868; DEVICE:CT-868 Pen Injector; DRUG:CT-868 Pen Injector, Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baseline [at Day 1 to Week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.